Live tape
Top 8, mentions 7d6,521META1,699 mentions▲ +0.06GOOGL1,264 mentions▲ +0.03NVDA837 mentions▲ +0.09TSLA628 mentions▲ +0.05MSFT558 mentions▲ +0.06AMZN536 mentions▲ +0.04SPY518 mentions▲ +0.04AAPL481 mentions▲ +0.06

Equity · Healthcare

ENTA

NASDAQ

Enanta Pharmaceuticals, Inc.

$13.74 +5.69% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 11 sessions
$16 $12 2 Jul 17 Jul

The line runs $15 on 2 July through $13.74 on 17 July, on a scale from $12 to $16. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ENTA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 11 sessions over that window: $15 on 2 July 2026 through $13.74 on 17 July 2026.

Market cap $400.2M
52-week range $6.50 – $16.85
Avg volume 43.8K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

ENTA insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 8 Aug 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Aug 2026 Rottinghaus Scott T. Chief Medical Officer Tax withheld 1,467 $20K

ENTA reported financials

SEC EDGAR XBRL

ENTA reported revenue of $65.3M for the fiscal year ended 30 Sep 2025. Net income over the same period was −$81.9M.

Figure Reported Period
Revenue $65.3M 30 Sep 2025 fiscal year
Net income −$81.9M 30 Sep 2025 fiscal year
Diluted EPS −$3.84 30 Sep 2025 fiscal year
Total assets $296.9M 30 Jun 2026 at period end
Total equity $101.1M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ENTA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q3 2026 $-0.67 —
31 Mar 2026 Q2 2026 $-0.45 —
31 Dec 2025 Q1 2026 $-0.42 —
30 Sep 2025 FY 2025 $-3.84 —
30 Jun 2025 Q3 2025 $-0.85 —
31 Mar 2025 Q2 2025 $-1.06 —
31 Dec 2024 Q1 2024 $-1.05 —
30 Sep 2024 FY 2024 $-5.48 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ENTA institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a ENTA position for the quarter ended 30 Jun 2026 — a combined $25.7M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Millennium Management Trimmed −27.0% shares 643,967 $9.4M
Renaissance Technologies Held (±25%) −16.2% shares 557,600 $8.1M
AQR Capital Management Held (±25%) −18.0% shares 256,870 $3.7M
Marshall Wace Trimmed −37.2% shares 131,995 $1.9M
Two Sigma Investments Trimmed −73.4% shares 71,162 $1.0M
Citadel Advisors Trimmed −80.6% shares 50,844 $741K
D. E. Shaw & Co. Trimmed −51.3% shares 34,539 $504K
Balyasny Asset Management New position 14,915 $217K
Man Group Exited
Tudor Investment Corp Exited

Source: SEC EDGAR 13F filings

ENTA fails-to-deliver

SEC CNS data

On 24 Aug 2026, 819 shares of ENTA failed to deliver (about $11K).

Settlement date Shares failed Notional % of shares out
24 Aug 2026 819 $11K 0.003%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in ENTA

STOCK Act disclosures

The most recent congressional trade disclosed in ENTA is a sale by Daniel S. Goldman (house, NY), dated 12 Jul 2023.

Date Member Type Amount
12 Jul 2023 filed 13 Aug 2023 Daniel S. Goldman house · Democrat–NY Sale $1K–$15K

Source: U.S. House of Representatives financial disclosures